tend to drop over time and can even become normal. Additionally, the prognostic value of pulmonary biopsy is also unclear. The absence of fibrosis, as in our patients, may be a marker of reversibility. Pulmonary vasodilators and ventricular assistance have been shown to be useful as a bridge to eligibility in both adult and pediatric patients,\(^3\) as they allow transplantation in patients initially rejected due to pulmonary hypertension. This strategy may be preferable to cardiopulmonary transplantation.

Ferran Gran,\(^a,^4\) Dimpna Albert,\(^b\) Joan Sanchez-de-Toledo,\(^b\) Joan Balcells,\(^b\) Joan Carles Ferreres,\(^b\) and Raül Abella\(^b\)

\(^a\)Unidad de Cardiología Pediátrica, Hospital Universitario de la Vall d’Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
\(^b\)Servicio de Cuidados Intensivos Pediátricos, Hospital Universitario de la Vall d’Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
\(^c\)Unidad de Cuidados Intensivos Pediátricos, Hospital Universitat Virgen de las Nieves, Granada, Spain
\(^d\)Servicio de Anatomía Patológica, Hospital Universitario de la Vall d’Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
\(^e\)Servicio de Cirugía Cardiaca Pediátrica, Hospital Universitario de la Vall d’Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain

**Nonvalvular Atrial Fibrillation: the Problem of an Undefined Definition**

**Fibrilación auricular no valvular: el problema de una definición indefinida**

**To the Editor,**

The term nonvalvular atrial fibrillation (NVAF) is used with increasing frequency to describe patients who may benefit from new oral anticoagulants (NOACs). This is a cause for concern for us because the European guidelines for the management of atrial fibrillation, dated 2012,\(^1\) state that “no uniform or satisfactory definition of these terms exists.” The indication for NOACs is based on 4 pivotal studies. To clarify this concept, we have reviewed the inclusion criteria in the protocols of these studies in terms of native valve lesions:

- The RE-LY study\(^2\) did not include the term NVAF. Patients with “hemodynamically relevant valve disease” were excluded and, as far as we are aware, a more precise definition was not included.

- The ROCKET trial\(^3\) was the only study that included the term NVAF. However, the protocol only excluded patients with “hemodynamically significant” mitral valve stenosis. For the indication of rivaroxaban, atrial fibrillation with a valve lesion other than mitral valve stenosis would not be considered NVAF.

- The authors of the ARISTOTLE trial\(^4\) and ENGAGE AF-TIMI 48 trial\(^5\) did not use the term. Both these trials excluded only patients with moderate or severe mitral valve stenosis.

A patient with severe aortic stenosis or mitral valve regurgitation with atrial fibrillation would not have been excluded from 3 of the 4 pivotal trials due to valve lesions. It would appear striking and inconsistent to describe such a patient as having NVAF. With valve disease, generalizations are inappropriate. Thus, thromboembolism as a pathophysiology mechanism for mitral stenosis cannot be considered similar to mitral valve regurgitation or pulmonary stenosis.

The use of a poorly defined term may lead to problems for certain therapeutic indications. To quantify the problem, we reviewed the echocardiography database of a secondary university hospital with no heart surgery facilities. In the last 6 months of
The clinical trials show that NOACs, or at least factor Xa antagonists, can be used in patients with atrial fibrillation who do not have mechanical prostheses and significant mitral valve stenosis, although they may have other valve lesions, whether or not they are significant. This point is essential, as atrial fibrillation is the most frequent sustained arrhythmia, while mitral valve stenosis is becoming less frequent. The term NVAF does not seem appropriate as an umbrella term for patients who may benefit from NOACs. Not only is this term not representative, but it is also not defined in the guidelines and may lead to inappropriate and uneven clinical management in the indications for anticoagulation. We are therefore of the opinion that this poorly defined term should not be used in this context.

CONFLICTS OF INTEREST

A. García Lledó has provided scientific advice to Bristol-Myers and Bayer and has given presentations and classes in courses sponsored by Pfizer and Boehringer.

Alberto García-Lledó,José-Luis Moya Mur,Javier Ballaguer Recena,Eva Díaz Caraballo,Javier García Pérez-Velasco, and Azucena Sanz Barrio

*Servicio de Cardiología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
+Departamento de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain
Servicio de Cardiología, Hospital Universitario de Guadalajara, Guadalajara, Spain

* Corresponding author:
E-mail address: alberto.garcia-lledo@uh.es (A. García-Lledó).
Available online 27 June 2014

REFERENCES


http://dx.doi.org/10.1016/j.heart.2014.03.009

Percutaneous Closure of Baffle Leaks in Patients With Atrial Switch Operation for D-Transposition of the Great Arteries

Cierre percutáneo de comunicaciones interauriculares en pacientes con cirugía de switch auricular para la D-transposición de grandes arterias

To the Editor,

The atrial switch procedure (Senning or Mustard technique) was the surgical standard of care for patients with D-transposition of the great arteries during the 1970s and 1980s. This intervention achieved redirection of systemic venous blood flow to the left ventricle (subpulmonary) and of the pulmonary venous flow to the right ventricle (systemic) by means of an atrial baffle. Interest in this topic is mainly due to the large number of patients currently being followed up after these interventions. The long-term complications of the atrial switch procedure are mainly related to right ventricular dysfunction, atrial bradyarrhythmias and tachyarrhythmias, pulmonary hypertension and baffle problems (leaks and/or obstructions). Baffle leaks have traditionally been surgically treated.

The main aim of our report is to describe the percutaneous approach for the treatment of baffle leaks and its clinical medium-term results in a tertiary hospital. From 2005 to 2012,

### Table

<table>
<thead>
<tr>
<th>Valve Lesions in 748 Patients With Atrial Fibrillation but Without Prostheses</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No lesion</td>
<td>5 (0.67)</td>
</tr>
<tr>
<td>Any grade VS or VR ≥ grade II</td>
<td>587 (78.5)</td>
</tr>
<tr>
<td>Any grade VS or VR ≥ grade III</td>
<td>472 (63.1)</td>
</tr>
<tr>
<td>Any grade MS</td>
<td>158 (21.1)</td>
</tr>
<tr>
<td>Moderate or severe MS</td>
<td>93 (12.4)</td>
</tr>
</tbody>
</table>

MS, mitral valve stenosis; VR, regurgitation of any valve; VS, stenosis of any valve.